Hamburg, Germany — TheNewswire --- February 20, 2024 — Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is delighted to report its participation at the 53rd annual meeting of the German Society for Thoracic, Heart and Vascular Surgery. The event, held Feb. 19, was held in conjunction with the annual meeting of the German Society for Paediatric Cardiology and Congenital Heart Defects in Hamburg, Germany.

Ventripoint's transformative technology, which uses a patented A.I. to convert inferior ultrasound images into MRI-grade analysis of the heart, was demonstrated by PD Dr Med. K.T. Laser, who actively uses Ventripoint in his clinical practice. You can see him in action

As a thought leader in paediatric cardiology, Dr. Laser is using the Ventripoint VMS+ to image patients at the HDZ NRW Heart and Diabetes Center in Germany. Dr. Laser's has reported that Ventripoint is an effective diagnostic tool that allows enhanced echocardiograms of infants and adults to be available faster and at less cost than a cardiac MRI with equivalent volumetric results.

"This was an important forum for Ventripoint to showcase our innovative A.I. technology to the German cardiology community," said Bart Hendriks, Ventripoint’s Strategic Partnerships Executive. "Our presence here allowed some of Europe’s top cardiologists and health institutions to learn about and work with our technology firsthand."

Ventripoint’s technology is now being used in leading hospitals in Europe, the UK, Canada, and the United States. The Company is now focused on expanding the user base of VMS+ in hospitals and clinics worldwide.

"I want to thank both Dr. Laser and Bart for their efforts at this important joint conference,” said Ventripoint’s Interim CEO Hugh MacNaught, who also attended the meetings. “Ventripoint is emerging as a rapid, cost-effective alternative to traditional MRI cardiac imaging. It’s now indisputable that our technology enables caregivers to provide MRI-grade analysis from inferior ultrasounds to more patients, swiftly and affordably, with high accuracy."

For further information, please contact:

Jonathan Robinson CFA

This email address is being protected from spambots. You need JavaScript enabled to view it.

(416) 669-1001

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws.